The prognostic ease and difficulty of invasive breast carcinoma

Cell Reports

Volumn 9, Issue 1, 2014, Pages 129-142

  Tofigh, Ali ^a,b   Suderman, Matthew ^a,b   Paquet, Eric R ^a,b   Livingstone, Julie ^a,b   Bertos, Nicholas ^a   Saleh, Sadiq M ^a,b,c   Zhao, Hong ^a   Souleimanova, Margarita ^a   Cory, Sean ^a,b   Lesurf, Robert ^a,b,c   Shahalizadeh, Solmaz ^b   GarciaLopez, Norberto ^c,g   Riazalhosseini, Yasser ^c,h   Omeroglu, Atilla ^e,g   Ursini Siegel, Josie ^d,e   Park, Morag ^a,c,e   Dumeaux, Vanessa ^e,f   Hallett, Michael ^a,b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f UNIVERSITY OF TROMSØ   (Norway)

^g MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^h MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; MOLECULAR MARKER; PROGESTERONE RECEPTOR; RECEPTOR SUBTYPE; TRANSCRIPTOME;

ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CELL PROLIFERATION; DISTANT METASTASIS; ENVIRONMENTAL FACTOR; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENOTYPE; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; HUMAN; INVASIVE CARCINOMA; NUCLEOTIDE SEQUENCE; PREVALENCE; STEM CELL; TUMOR VOLUME; BREAST NEOPLASMS; DISEASE FREE SURVIVAL; FEMALE; GENETICS; PATHOLOGY; PROGNOSIS; SURVIVAL;

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; PROGNOSIS; SURVIVAL ANALYSIS; TRANSCRIPTOME;

EID: 84907964639     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.08.073     Document Type: Article

References (39)

1. Aparicio S., Caldas C. The implications of clonal genome evolution for cancer medicine. N.Engl. J. Med. 2013, 368:842-851.
2. Curtis C., Shah S.P., Chin S.F., Turashvili G., Rueda O.M., Dunning M.J., Speed D., Lynch A.G., Samarajiwa S., Yuan Y., et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352. METABRIC Group.
3. Desmedt C., Haibe-Kains B., Wirapati P., Buyse M., Larsimont D., Bontempi G., Delorenzi M., Piccart M., Sotiriou C. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin. Cancer Res. 2008, 14:5158-5165.
4. Deyarmin B., Kane J.L., Valente A.L., van Laar R., Gallagher C., Shriver C.D., Ellsworth R.E. Effect of ASCO/CAP guidelines for determining ER status on molecular subtype. Ann. Surg. Oncol. 2013, 20:87-93.
5. Gruvberger S., Ringnér M., Chen Y., Panavally S., Saal L.H., Borg A., Fernö M., Peterson C., Meltzer P.S. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res. 2001, 61:5979-5984.
6. Guedj M., Marisa L., de Reynies A., Orsetti B., Schiappa R., Bibeau F., MacGrogan G., Lerebours F., Finetti P., Longy M., et al. A refined molecular taxonomy of breast cancer. Oncogene 2012, 31:1196-1206.
7. Haibe-Kains B., Desmedt C., Loi S., Culhane A.C., Bontempi G., Quackenbush J., Sotiriou C. A three-gene model to robustly identify breast cancer molecular subtypes. J.Natl. Cancer Inst. 2012, 104:311-325.
8. Harbeck N., Rody A. Lost in translation? Estrogen receptor status and endocrine responsiveness in breast cancer. J.Clin. Oncol. 2012, 30:686-689.
9. Harbeck N., Sotlar K., Wuerstlein R., Doisneau-Sixou S. Molecular and protein markers for clinical decision making in breast cancer: today and tomorrow. Cancer Treat. Rev. 2014, 40:434-444.
10. Hornberger J., Alvarado M.D., Rebecca C., Gutierrez H.R., Yu T.M., Gradishar W.J. Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review. J.Natl. Cancer Inst. 2012, 104:1068-1079.
11. Ioannidis J.P., Allison D.B., Ball C.A., Coulibaly I., Cui X., Culhane A.C., Falchi M., Furlanello C., Game L., Jurman G., et al. Repeatability of published microarray gene expression analyses. Nat. Genet. 2009, 41:149-155.
12. Iwamoto T., Pusztai L. Predicting prognosis of breast cancer with gene signatures: are we lost in a sea of data?. Genome Med. 2010, 2:81.
13. Iwamoto T., Booser D., Valero V., Murray J.L., Koenig K., Esteva F.J., Ueno N.T., Zhang J., Shi W., Qi Y., et al. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J.Clin. Oncol. 2012, 30:729-734.
14. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
15. Jönsson G., Staaf J., Vallon-Christersson J., Ringnér M., Holm K., Hegardt C., Gunnarsson H., Fagerholm R., Strand C., Agnarsson B.A., et al. Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Res. 2010, 12:R42.
16. Krumm N., Sudmant P.H., Ko A., O'Roak B.J., Malig M., Coe B.P., Quinlan A.R., Nickerson D.A., Eichler E.E. Copy number variation detection and genotyping from exome sequence data. Genome Res. 2012, 22:1525-1532. NHLBI Exome Sequencing Project.
17. Landmark-Høyvik H., Dumeaux V., Nebdal D., Lund E., Tost J., Kamatani Y., Renault V., Børresen-Dale A.L., Kristensen V., Edvardsen H. Genome-wide association study in breast cancer survivors reveals SNPs associated with gene expression of genes belonging to MHC class I and II. Genomics 2013, 102:278-287.
18. Lehmann B.D., Bauer J.A., Chen X., Sanders M.E., Chakravarthy A.B., Shyr Y., Pietenpol J.A. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J.Clin. Invest. 2011, 121:2750-2767.
19. Montemurro F., Di Cosimo S., Arpino G. Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. Ann. Oncol. 2013, 24:2715-2724.
20. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., Baehner F.L., Walker M.G., Watson D., Park T., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N.Engl. J. Med. 2004, 351:2817-2826.
21. Parker J.S., Mullins M., Cheang M.C., Leung S., Voduc D., Vickery T., Davies S., Fauron C., He X., Hu Z., et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J.Clin. Oncol. 2009, 27:1160-1167.
22. Parl F.F., Schmidt B.P., Dupont W.D., Wagner R.K. Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading. Cancer 1984, 54:2237-2242.
23. Perou C.M., Sørlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
24. Poole E.M., Shu X., Caan B.J., Flatt S.W., Holmes M.D., Lu W., Kwan M.L., Nechuta S.J., Pierce J.P., Chen W.Y. Postdiagnosis supplement use and breast cancer prognosis in the After Breast Cancer Pooling Project. Breast Cancer Res. Treat. 2013, 139:529-537.
25. Prat A., Parker J.S., Karginova O., Fan C., Livasy C., Herschkowitz J.I., He X., Perou C.M. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010, 12:R68.
26. Prat A., Adamo B., Cheang M.C., Anders C.K., Carey L.A., Perou C.M. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist 2013, 18:123-133.
27. Rakha E.A., Reis-Filho J.S., Ellis I.O. Combinatorial biomarker expression in breast cancer. Breast Cancer Res. Treat. 2010, 120:293-308.
28. Reis-Filho J.S., Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 2011, 378:1812-1823.
29. Rouzier R., Perou C.M., Symmans W.F., Ibrahim N., Cristofanilli M., Anderson K., Hess K.R., Stec J., Ayers M., Wagner P., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 2005, 11:5678-5685.
30. Sørlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 2001, 98:10869-10874.
31. Sotiriou C., Pusztai L. Gene-expression signatures in breast cancer. N.Engl. J. Med. 2009, 360:790-800.
32. Staaf J., Jönsson G., Ringnér M., Vallon-Christersson J., Grabau D., Arason A., Gunnarsson H., Agnarsson B.A., Malmström P.O., Johannsson O.T., et al. High-resolution genomic and expression analyses of copynumber alterations in HER2-amplified breast cancer. Breast Cancer Res. 2010, 12:R25.
33. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102:15545-15550.
34. Ursini-Siegel J., Cory S., Zuo D., Hardy W.R., Rexhepaj E., Lam S., Schade B., Jirstrom K., Bjur E., Piccirillo C.A., et al. Receptor tyrosine kinase signaling favors a protumorigenic state in breast cancer cells by inhibiting the adaptive immune response. Cancer Res. 2010, 70:7776-7787.
35. van 't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
36. van Vliet M.H., Reyal F., Horlings H.M., van de Vijver M.J., Reinders M.J., Wessels L.F. Pooling breast cancer datasets has a synergetic effect on classification performance and improves signature stability. BMC Genomics 2008, 9:375.
37. Venet D., Dumont J.E., Detours V. Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Comput. Biol. 2011, 7:e1002240.
38. Weigelt B., Baehner F.L., Reis-Filho J.S. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J.Pathol. 2010, 220:263-280.
39. Wirapati P., Sotiriou C., Kunkel S., Farmer P., Pradervand S., Haibe-Kains B., Desmedt C., Ignatiadis M., Sengstag T., Schütz F., et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008, 10:R65.